{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:05:08Z","timestamp":1780524308236,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.05.023","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T20:00:23Z","timestamp":1495224023000},"page":"3548-3557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Aurelio P.","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso Carmona","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Infante","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos Tejedor","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily Yin","family":"Weckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Junior","given":"Edson Duarte","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhem","family":"Mensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.023_b0005","unstructured":"World Health Organization (WHO). Meningococcal meningitis fact sheet 141. Updated February 2015. Available from: [accessed 2017 January 19] http:\/\/www.who.int\/mediacentre\/factsheets\/fs141\/en\/."},{"key":"10.1016\/j.vaccine.2017.05.023_b0010","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martinon-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2017.05.023_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2017.05.023_b0020","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/civ506","article-title":"Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: A subjective role for serogroup and clonal complex","volume":"61","author":"Stoof","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.023_b0025","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2017.05.023_b0030","doi-asserted-by":"crossref","first-page":"S594","DOI":"10.1093\/cid\/civ508","article-title":"Modeling long-term vaccination strategies with MenAfriVac in the African meningitis belt","volume":"61","author":"Karachaliou","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.023_b0035","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","article-title":"Global incidence of serogroup B invasive meningococcal disease: a systematic review","volume":"15","author":"Sridhar","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.023_b0040","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4161\/hv.29218","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)","volume":"10","author":"Esposito","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.05.023_b0045","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.023_b0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.05.023_b0055","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.05.023_b0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.05.023_b0065","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.05.023_b0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/21645515.2015.1091131","article-title":"Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.05.023_b0075","unstructured":"Ladhani SN, Parikh SR, Campbell H, Beebeejaun K, Ribeiro S, Yarwood J, Borrow R, Ramsay, ME. Invasive meningococcal disease in infants following the introduction of Bexsero\u00ae into the national immunisation programme in England [abstract 03]. In: Program and abstracts of the 20th international pathogenic neisseria conference, 4th-9th September 2016. Manchester, United Kingdom."},{"key":"10.1016\/j.vaccine.2017.05.023_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","author":"Parikh","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2017.05.023_b0085","unstructured":"Public Health England. Immunisation against meningococcal B disease for infants aged from two months. Information for healthcare professionals. Available from: [accessed 2017 January 19] https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/501588\/PHE_MenB_informationforhealthprofessionals_FINAL_18022016.pdf"},{"key":"10.1016\/j.vaccine.2017.05.023_b0090","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jinf.2015.09.035","article-title":"The introduction of the meningococcal B (MenB) vaccine (Bexsero\u00ae) into the national infant immunisation programme-New challenges for public health","volume":"71","author":"Ladhani","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2017.05.023_b0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O'Ryan","year":"2014","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.05.023_b0100","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.023_b0105","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.023_b0110","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.023_b0115","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.05.023_b0120","doi-asserted-by":"crossref","first-page":"e00163","DOI":"10.1128\/mBio.00163-13","article-title":"Conservation of meningococcal antigens in the genus Neisseria","volume":"4","author":"Muzzi","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2017.05.023_b0125","doi-asserted-by":"crossref","first-page":"E215","DOI":"10.1503\/cmaj.141200","article-title":"Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months","volume":"187","author":"McQuaid","year":"2015","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2017.05.023_b0130","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2017.05.023_b0135","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.vaccine.2016.11.009","article-title":"Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial","volume":"35","author":"Iro","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.023_b0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.023_b0145","unstructured":"Institut National de Sant\u00e9 Publique du Qu\u00e9beq. Rapport int\u00e9rimaire de surveillance de la s\u00e9curit\u00e9 de la premi\u00e8re dose du vaccin contre le m\u00e9ningocoque de s\u00e9rogroupe B au Saguenay\u2013Lac-Saint-Jean. Available from: [accessed 2017 January 19] https:\/\/www.inspq.qc.ca\/pdf\/publications\/1885_Vaccin_Menincogoque_SerogroupeB.pdf"},{"key":"10.1016\/j.vaccine.2017.05.023_b0150","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.023_b0155","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.023_b0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W strain","volume":"22","author":"Ladhani","year":"2016","journal-title":"England Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.023_b0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3201\/eid2206.151093","article-title":"Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection","volume":"22","author":"Whelan","year":"2016","journal-title":"Norway. Emerg Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730631X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730631X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T19:13:44Z","timestamp":1659035624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1730631X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":33,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X1730631X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}